POZ - African American Hub : Treatment News : New Wave of Transmitted Drug Resistance Predicted for San Francisco

POZ African American / Black Hub
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:
African American Hub News
 

Back to home » News & Views » Treatment News


 

March 2011
February 2011
January 2011
December 2010
November 2010
October 2010
September 2010
August 2010
July 2010
June 2010
May 2010
April 2010
March 2010
February 2010
January 2010
December 2009
November 2009
October 2009
September 2009
August 2009
July 2009
June 2009
May 2009
April 2009
March 2009
February 2009
January 2009
December 2008
November 2008
October 2008
September 2008
August 2008
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007
November 2007
October 2007
September 2007
August 2007
July 2007
June 2007
May 2007
April 2007
March 2007
February 2007


emailrssprint

January 15, 2010

New Wave of Transmitted Drug Resistance Predicted for San Francisco

The number of new HIV infections with virus resistant to HIV drugs known as non-nucleoside reverse transcriptase inhibitors (NNRTIs) could rise significantly in San Francisco and become a self-sustaining epidemic, according to a study published online January 14 in the journal Science and reported by Bloomberg News. The authors also fear that an upswing in transmitted drug-resistant virus could imperil efforts to test and treat nearly everyone living with HIV in developing countries.

Transmitted drug resistance (TDR) is an ever-present concern for scientists, physicians and people with HIV. When people with drug-resistant HIV pass their virus to others, those newly infected people have fewer treatment options.

Thus far, TDR has remained fairly stable at about 14 percent or less of new infections in many Western countries. About 75 percent of TDR HIV cases in San Francisco involve virus resistant to NNRTIs, such as Sustiva (efavirenz) and Viramune (nevirapine).

To determine whether TDR is likely to remain stable or to grow in San Francisco, a group of biomedical mathematicians led by Sally Blower, PhD, from the University of California in Los Angeles, devised a mathematical model of TDR. This model took into account current trends, as well as the likely infectiousness of different strains of drug-resistant virus.

Blower’s team found that although most TDR strains are not likely to rise significantly, there is lingering concern with transmitted NNRTI-resistant strains. “If only 70 percent [of people on NNRTIs] are virally suppressed, NNRTI-resistance could increase by more than 30 percent,” Blower explained.

“Our results have shown that effective treatments have prevented TDR from increasing to greater than 15 percent in San Francisco,” she continued. “However, our modeling shows the network is continuing to evolve. Disturbingly, we found the majority of the resistant strains currently being transmitted in this city are capable of causing self-sustaining epidemics…. We predict a wave of NNRTI-resistant strains will emerge over the next five years in San Francisco due to transmission from untreated individuals.”

The model also has Blower and her colleagues fearing that the potential wave of new TDR in San Francisco could have dire implications for the developing world—where the choice of second-line regimens is extremely limited. Blower explained that resistance is most likely to develop against NNRTIs, compared with other current HIV drugs, and that NNRTIs are used almost universally as first-line treatment in the developing world.

Some experts have proposed a massive “test and treat” campaign to test most people for HIV and provide ARV treatment as a way to increase survival among people with HIV and prevent new infections.

Blower, however, cautions against this approach. “Universal test and treat is just a recipe for disaster,” she told Bloomberg News. “Our modeling is saying the drug resistant strains that you will generate from this kind of strategy are ones that will be very strong, transmissible, and therefore you will get an awful lot of problems.”

NEW! Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

| Posting Rules

Previous Comments:

  comments 1 - 1 (of 1 total)    

Chad, San Francisco, 2010-01-20 16:49:02
So the lesser of two evils is not discovering the true scope of the disease and providing universal access to care because it would lead to more TDR? The virus has and will mutate no matter what we do. Might as well care for those we can and work out another treatment for the 30%.

comments 1 - 1 (of 1 total)    


[Go to top]

Featured Video
Do you believe we can end AIDS? To find out how you can help, click here.
Get Answers
What to do if you've just been diagnosed
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS


    blue_water
    New York City
    New York


    UPPinAction
    New Brunswick
    New Jersey


    gustavthesolid
    New York
    New York


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2012 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.